{
    "symbol": "DBVT",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-02 18:33:04",
    "content": " Before we begin, please note that today\u2019s call may include a number of forward-looking statements, including, but not limited to comments regarding our clinical and regulatory development plans, the timing and results of interactions with regulatory agencies, our forecast of our car of our cash runway and the ability of any of our product candidates, if approved, to improve the lives of patients with food allergies. As such, we have named the new pivotal trial VITESSE, which means speed in French and stands for Viaskin Peanut immunotherapy trial to evaluate safety, simplicity and efficacy, V-I-T-E-S-S-E. At the time of our last corporate update in early March, we had completed the VITESSE protocol and prepared it for submission to the FDA for their review."
}